Clinical Trials Logo

Rheumatic Heart Disease clinical trials

View clinical trials related to Rheumatic Heart Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06150274 Not yet recruiting - Clinical trials for Rheumatic Heart Disease

Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy

CROSSVal
Start date: May 2024
Phase: N/A
Study type: Interventional

The goal of this randomised study is comparison of wire assisted balloon mitral valvulotomy to standard Inoue balloon technique on patients with rheumatic mitral stenosis. The main question it aims to answer is whether procedure time is reduced using the wire assisted method. Participants will be randomized to one of the two methods.

NCT ID: NCT06097585 Not yet recruiting - Heart Failure Clinical Trials

Gliflozins on HF in Regurgitant Rheumatic Heart

Start date: December 1, 2023
Phase:
Study type: Observational

The objective of this trial is to detect impact of Gliflozin on patients with heart failure due to reurgitant rheumatic valve disease

NCT ID: NCT06002243 Not yet recruiting - Clinical trials for Rheumatic Heart Disease

Non-Expert Acquisition & Remote Expert Review of Screening Echocardiography Images From Child Health & AnteNatal Clinics

NEARER SCAN
Start date: April 2024
Phase: N/A
Study type: Interventional

The Non-Expert Acquisition and Remote Expert Review of Screening echocardiography images from Child health and AnteNatal clinics (NEARER SCAN) study is a co-designed, implementation research project that will improve equitable access to culturally safe, best quality care for Rheumatic Heart Disease (RHD) in high-burden Aboriginal and Torres Strait Islander communities in Australia, and in Timor-Leste. The research addresses an area of unmet need, using novel technologies and embedding them in health practice, to enhance and accelerate diagnosis of RHD outside acute health settings and improve outcomes. The study will be conducted in partnership with community leaders and local partners.

NCT ID: NCT05682196 Not yet recruiting - Clinical trials for Rheumatic Heart Disease in Children

Rituximab in Patients With Acute Rheumatic Fever

AGRAF-2
Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Acute Rheumatic Fever is an autoimmune inflammatory post-infectious syndrome, mainly caused by type A streptococcus. It is characterized as an inadequate immune response. It may provoke carditis, combined with articular, skin and neurologic signs. Only carditis, prevalent in 60% of acute rheumatic diseases, may provoke valvular sequels, which define rheumatic cardiopathy. Antibiotherapy based on penicillin is the standard treatment of both acute rheumatic fever and its prevention. Although no anti-inflammatory treatment has proved its efficacy, with or without steroids anti-inflammatory treatments are administered in acute episode of ARF. Up to date, only prevention strategies have shown efficacy.

NCT ID: NCT05618223 Not yet recruiting - Heart Failure Clinical Trials

Dapagliflozin Effect on Rheumatic Mitral Stenosis

Dapa-Rhemis
Start date: December 1, 2022
Phase: Phase 3
Study type: Interventional

Rheumatic mitral stenosis remains a health problem in developing countries. Progressive fibrosis of the valves and myocardium is the main pathophysiology that plays an important role. Dapagliflozin has various beneficial effects on the heart by reducing fibrosis, reducing inflammation, and improving patient quality of life. However, the role of this therapy is unknown in patients with rheumatic mitral stenosis.

NCT ID: NCT03549052 Not yet recruiting - Clinical trials for Right Ventricular Dysfunction

Right Ventricular Echo Assessment in Mitral Valve Replacement

Start date: June 1, 2018
Phase:
Study type: Observational

Rheumatic heart disease remains a major health problem in developing countries. It is the most important sequel of rheumatic fever and occurs in about 30% of patients with rheumatic fever.Rheumatic heart disease presents with different degrees of pancarditis and associated valve failure. Involvement of the mitral leaflets can cause mitral regurgitation (MR) or stenosis and eventually can lead to heart failure. Mitral repair or replacement is therefore recommended before left ventricular (LV) dysfunction develops. Study Objectives/Specific Aims Overall Goal: To determine the benefit the patient with pulmonary hypertension will get from mitral valve replacement as regard function improvement and remodeling of the right ventricle. - Objective1: Identify risk factors that are predictive of outcomes.(Type and severity of Mitral valve pathology , severity of pulmonary hypertension, tricuspid regurge, preoperative RV dysfunction) - Objective2: Determine the value of management strategies (Mitral valve replacement in pulmonary hypertension i.e. : decrease RV pressure overload and enhance RV remodeling) - Objective3: Assessment of the outcomes clinically & Echocardiographically : postoperative results during hospital stay and follow up (short term up to 3 months).